The next generation biopharma leader

Transcription

1 The next generation biopharma leader Half Year 2008 Results UCB Group Analysts and Investors Presentation Lloyd and Alexander, living with epilepsy August 1, 2008

2 Disclaimer and safe harbour 2 Forward-looking statements: This presentation includes "forward-looking statements" relating to UCB and Schwarz Pharma that are subject to known and unknown risks and uncertainties, many of which are outside of UCB s and Schwarz Pharma s control and are difficult to predict, that may cause actual results to differ materially from any future results expressed or implied from the forward-looking statements. In this presentation, the words "anticipates," "believes," "estimates," "seeks," "expects," "plans," "intends" and similar expressions, as they relate to UCB or Schwarz Pharma, are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from such expectations include, without limitation: the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms; the inability to integrate successfully Schwarz Pharma within UCB or to realize synergies from such integration following the acquisition; costs related to the acquisition of Schwarz Pharma; the economic environment of the industries in which UCB and Schwarz Pharma operate; costs associated with research and development; changes in the prospects for products in the pipeline or under development by UCB or Schwarz Pharma; dependence on the existing management of UCB and Schwarz Pharma; changes or uncertainties in Belgian or German tax laws or the administration of such laws; changes or uncertainties in the laws or regulations applicable to the markets in which UCB and Schwarz Pharma operate. All written and oral forward-looking statements attributable to UCB or Schwarz Pharma or persons acting on either of their behalf are expressly qualified in their entirety by the cautionary statements above. Neither UCB nor Schwarz Pharma intend, or undertake any obligation, to update these forward-looking statements.

3 Agenda 3 Commercial Highlights 2008 Roch Doliveux Financial results HY 2008 & Synergies Detlef Thielgen Pipeline update & Milestones ahead in 2008 Iris Loew-Friedrich Vimpat Epilepsy Troy Cox Strategy update & Outlook 2008 Roch Doliveux

4 Commercial Highlights Roch Doliveux Chief Executive Officer Commercial highlights Cimzia launch Launch plans Neupro in RLS Vimpat in epilepsy

5 Commercial highlights 5 Keppra dynamic growth: +20% to 597 million U.S. sales of 371 million up 16%, with 34.9% market share 1 EU sales of 202 million up 26%, with 31.7% market share 1 Pediatric exclusivity granted by the FDA Sustained uptake of Neupro in EU despite U.S. recall EU sales of 30 million up 134%, with 14.5% market share 2 U.S. sales of 5 million Xyzal stable EU and ROW sales of 102 million Xyzal successful US launch 3 with a NRx market share of 12.5% 4 oral solution approved in the USA in January Source: IMS Midas Epilepsy only, MAT May Source: IMS Midas - YTD May 2008 EU3=Germany+UK+Spain not restricted to Pd or RLS 3 no consolidation of US sales as of profit sharing agreement with sanofi-aventis 4 IMS NPA Weekly as of All sales mentioned above are UCB's net sales

6 Keppra Market leader in the U.S U.S. - Market share in value (%) - Epilepsy only - MAT 34.9% 5 0 May 2003 May 2004 May 2005 May 2006 May 2007 May 2008 Keppra gabapentin lamotrigine oxcarbazepine topiramate zonisamide Source: IMS Midas

7 Keppra Market leader in Europe EU - Market share in value (%) - Epilepsy only - MAT 31.7% 5 0 May 2003 May 2004 May 2005 May 2006 May 2007 May 2008 Keppra gabapentin lamotrigine oxcarbazepine topiramate zonisamide Source: IMS Midas EU5

8 Commercial highlights 8 Keppra dynamic growth: +20% to 597 million U.S. sales of 371 million up 16%, with 34.9% market share 1 EU sales of 202 million up 26%, with 31.7% market share 1 Pediatric exclusivity granted by the FDA Sustained uptake of Neupro in EU despite U.S. recall EU sales of 30 million up 134%, with 14.5% market share 2 U.S. sales of 5 million Xyzal stable EU and ROW sales of 102 million Xyzal successful US launch 3 with a NRx market share of 12.5% 4 oral solution approved in the USA in January Source: IMS Midas Epilepsy only, MAT May Source: IMS Midas - YTD May 2008 EU3=Germany+UK+Spain not restricted to Pd or RLS 3 no consolidation of US sales as of profit sharing agreement with sanofi-aventis 4 IMS NPA Weekly as of All sales mentioned above are UCB's net sales

9 Commercial highlights 9 Keppra dynamic growth: +20% to 597 million U.S. sales of 371 million up 16%, with 34.9% market share 1 EU sales of 202 million up 26%, with 31.7% market share 1 Pediatric exclusivity granted by the FDA Sustained uptake of Neupro in EU despite U.S. recall EU sales of 30 million up 134%, with 14.5% market share 2 U.S. sales of 5 million Xyzal stable EU and ROW sales of 102 million Xyzal successful U.S. launch 3 with a NRx market share of 12.5% 4 oral solution approved in the U.S. in January Source: IMS Midas Epilepsy only, MAT May Source: IMS Midas - YTD May 2008 EU3=Germany+UK+Spain not restricted to Pd or RLS 3 no consolidation of US sales as of profit sharing agreement with sanofi-aventis 4 IMS NPA Weekly as of All sales mentioned above are UCB's net sales

10 Xyzal surpasses Clarinex (NRx share without Singulair ) 10 NRx Market Shares 14% 12% 10% 8% 6% 4% U.S vs 2007 New prescriptions (NRx) Share -prescribed anti-histamines in adults 12.5% 11.1% 2% 0% Oct-07 Nov-07 Dec-07 Jan-08 Feb-08 Mar-08 Apr-08 May-08 Jun-08 Xyzal Clarinex Source: NRx share (IMS NPA Weekly data through June 27, 2008)

11 Xyzal #1 prescribed antihistamine among specialists 11

12 Launches, Launches, Launches 12 Cimzia in Crohn's disease launched in Switzerland (Jan. 2008) Cimzia in Crohn's disease launched in the U.S. (April 2008) Immediate launch, products available to patients within less than 48 hours Launch of Vimpat for epilepsy in first European countries planned for September 2008 Europe: CHMP positive opinion (June 2008) Launch of Neupro for RLS in Europe expected H Europe: CHMP positive opinion (April 2008) Manufacturing variation filed (July 2008)

13 Cimzia in Crohn's disease Launched in the U.S. End of April 13 Cimzia -A New Generation The First and Only PEGylated anti-tnf Sustainable Results Every 4 weeks stable dosing "CIMplicity Service Center" Health insurance verification Free trial and co-pay assistance Home health nurse program

14 Cimzia in Crohn's disease Launch in the U.S. first update 14 Over patients on Cimzia to date U.S. Market share in July achieved 7% * Gain biologic naïve patients 60% of patients are naïve Significant CIMplicity enrollments Over gastroenterologists have enrolled Efficacy message well received (6-weeks post-launch study) PEGylation is considered unique and highly motivating 72% of surveyed gastroenterologists state that they will increase their prescribing of Cimzia * Source: Medical Radar, patient share ** IMS & internal estimate, Rx

15 15 Detlef Thielgen Chief Financial Officer 2008 Half-Year Financial Results Synergies

16 Financial highlights HY Revenue decreased by 217 million (-11%) to million Zyrtec net sales alone decreased by 166 million (-56%) to 132 million Total operating expenses decreased by 8% driven by: Substantial M&S synergies despite launch costs R&D expenses partially offset by synergies G&A continued saving due to synergies Recurring EBITDA of 358 million (-26%) Net profit amounted to 108 million (-37%)

17 Top 5 selling products & new launches A strong foundation 17 million H Top Sellers YTD Change Actual rates Constant rates Keppra % 32% Zyrtec (incl. D/Cirrus ) % -55% Xyzal % -0% omeprazole 45-50% -42% Tussionex 73 35% 56% New product launched Neupro % 115% Cimzia Total net sales % -4% 1 excluding Xyzal US revenue of 19 million from profit sharing with sanofi-aventis

18 HY 2008 net sales Therapeutic areas 18 Other products 35% HY 2008 net sales million Allergy 15% CNS 50% UCB H net sales Other products 37% million Allergy 24% CNS 39% Products included in CNS franchise: Keppra, Metadate /Equasym, Nootropil, Neupro, Atarax, Xyrem

19 HY 2008 net sales Geographic diversification 1 19 H net sales Europe 48% million Rest of World 13% North America 39% H net sales million Europe 42% Rest of World 13% North America 45% * 1 sales by destination

20 Recurring EBITDA 20 (IFRS, million) Revenue Net sales Royalty income & fees Other revenue Gross profit 1 excluding inventory step-up Marketing & Selling expenses Research & Development expenses General & Administrative expenses Other operating income/(expenses) Recurring EBIT excluding inventory step-up H (455) (370) (119) (6) H (529) (374) (135) Change in % -11% -9% -44% 0-10% -16% -14% -1% -12% -16% -35% Amortisation of intangible assets % Depreciation charges % One-time inventory step up - 94 Recurring EBITDA %

21 Net profit 21 (IFRS, million) Recurring EBIT Impairment charges Restructuring expenses Other non recurring income/(expenses) EBIT (Operating profit) Net financial expenses Income tax expense Net Profit 1 H (34) (5) 224 (69) (48) 108 H (5) (43) (77) (61) 171 Change in % -16% -21% -88% -27% -10% -21% -37% 1 after minority interest

22 Balance sheet 22 million Non current assets Intangible assets Goodwill Other non-current assets Current assets Total assets Shareholders' equity Capital and reserves Profit for the period H Dec Minority interests 1 1 Non current liabilities Current liabilities Total liabilities and shareholder's equity

23 Cash flow 23 million Net profit from continuing operation Non cash items Change in working capital Cash flow from operating activities Cash flow from investing activities of which tangible fixed assets purchase of which intangible fixed assets purchase of which related to Schwarz Pharma acquisition of which divestments Free cash flow from continuing operations Cash flow from financing activities H (65) (59) (14) (9) (79) H (6) 206 (10) (120) (17) (134) (590) June 2008 Dec 2007 Net debt (1 860) (1 915) Liquid assets Financial debt (2 400) (2 420)

24 Integration completed Synergies of 380m approx. two years ahead 24 HY 2008 Synergies: 305 million FY 2008 Synergies confirmed to reach more than 350 million: Supply Chain 12% Support functions 10% M&S 50% R&D 28% Original target September 2006: 300m by 2010, raised to 380m in July 2007 Reminder to reach 380m is just annualized impact

25 Late stage pipeline update 25 Iris Loew-Friedrich Chief Medical Officer Major achievements of H Update on clinical development of 2008

26 Neupro in Parkinson's disease Update 26 Implementation of full cold-chain in Europe ongoing Majority of stock has been replaced by refrigerated Neupro Variation under review by the EMEA Our target is to make Neupro available again to all patients (including new patients) in Europe by first half 2009 Evaluating various options: UCB is collecting data and working on Cold chain Process improvement Re-formulation To resolve U.S. out of stock situation In 2009 UCB aims to initiate a dialog with the FDA about a potential re-launch in the U.S. Data to support this dialog are currently being collected and evaluated

27 Rich late stage R&D pipeline 27 Phase I Anti-sclerostin Bone loss disorders Phase II Lacosamide Migraine prophylaxis Fibromyalgia Rotigotine nasal spray Restless legs syndrome (RLS) Rotigotine patch Fibromyalgia CDP323 Multiple sclerosis Phase III Vimpat Epilepsy monotherapy - USA Brivaracetam Epilepsy Keppra XR Epilepsy monotherapy - USA Xyrem Fibromyalgia CMC544 Non-Hodgkin lymphoma Filed Vimpat Epilepsy adjunctive therapy EU 4 + USA Diabetic neuropathic pain - EU + USA Neupro Advanced Parkinson's - USA Restless legs syndrome (RLS) EU 3 + USA Keppra XR Epilepsy - USA Cimzia Crohn's disease EU 2 Rheumatoid arthritis - EU + USA Fesoterodine Overactive bladder USA 1 Epratuzumab Lupus CDP791 Non-small-cell lung cancer Inflammation CNS Oncology Other 1 approved in EU 2 Cimzia approved and launched in the USA (April 2008) 3 Neupro positive opinion in EU (April 2008) 4 Vimpat positive opinion for EU (June 2008)

28 Multiple regulatory milestones and first approvals 28 Two regulatory approvals and one pediatric exclusivity Xyzal Oral solution in the U.S. Cimzia Crohn's disease was launched in the U.S. only 48 hours after approval Keppra pediatric exclusivity in epilepsy granted by FDA Two CHMP positive opinions for Europe Neupro treatment of Restless Legs Syndrome (RLS) Vimpat for adjunctive therapy in epilepsy Four filings U.S. EU Keppra XR Epilepsy Jan Keppra Epilepsy/infants and children* Jun Cimzia Rheumatoid arthritis Feb Jul * For children with epilepsy, aged from one month to under four years.

29 Update on clinical development of 2008 CDP791 in non-small cell lung cancer Following encouraging Phase II results, UCB is evaluating partnership options Fibromyalgia Lacosamide: Inconclusive Phase IIa headline results were reported in June 08, decision to start Phase IIb will be made by the end of the year Rotigotine: First Phase II results to be reported at end of H2/2008 Xyrem : First Phase III preliminary results to be reported at the end of H2/2008 Evaluation of further developments or alternatives for Cimzia in psoriasis UCB is commencing efforts to develop additional indications in rheumatology Not-approvable letter from FDA for Vimpat for diabetic neuropathic pain UCB to work closely with FDA to determine what specific actions are required to address the Agency s request. 29

30 Vimpat Diabetic neuropathic pain strong efficacy - Results (400mg) 30 Treatment effect of Lacosamide in double-blind trials (primary endpoint) SP614 SP742 SP768 SP743 SP Data will be presented at the "World Congress of Pain" in Glasgow, end of August P= * P= * P= ( * ) P= P= * Placebo 400mg/day ST + SP 746-1: Controlled withdrawal subtrial 1 different design: 4 week-maintenance only

31 Lacosamide Pain Relevance of Longterm Efficacy SP746-1: Controlled withdrawal subtrial 31 Change from baseline in 7 day Av. Pain Score Change from Baseline in Pain Scores for combined Study Periods A Patient Sequence B LCM LCM PBO LCM LCM PBO LCM LCM 0 Combined LCM Maintenance pre-pbo Mean pain score at withdrawal study baseline was 2.6 Mean baseline pain score in the prior randomized trial was 6.5 Combined PBO Combined LCM Titration post-pbo

32 Lacosamide: low PR interval effect compared to medicinal products recognised as safe 32 PR (ms) LCM LCMa* a * LCMb* b * PGBa* a * LTGa* a CBZ CBZb b Atazanavir Azatanavirb* b * Diltiazema a Verapamilb b AED HIV Hypertension a patients b healthy volunteers * placebo subtracted LCM Lacosamide PGB Pregabalin LTG Lamotrigene CBZ Carbamazepine

33 Vimpat (lacosamide) Epilepsy Troy Cox, Senior Vice President UCB & President CNS Operations 33

34 Epilepsy Serious disorder affecting many patients Most common serious neurological disorder Recurrent seizures resulting from excessive electrical activity in the brain Prevalence: 6 million people in top 7 markets million in EU5 2.4 million in U.S. 1.1 million in Japan Market size 2.3 billion (2007) Lloyd Estimated CAGR 1 : 3% (2004 to 2014) 1 Compound Annual Growth Rate Source: PatientBase - Decision Resources Epilepsy and IMS, Mat in epilepsy only the next generation biopharma leader 34

35 Major unmet medical need High unmet medical need in ~1/3 of treated epilepsy patients 50% 25-30% 20-25% Controlled on 1st Monotherapy Uncontrolled despite 2-3 AEDs "Controlled" on more than 1 AED 20-30% Patients with only 1 seizure/month report significant impact on their social life, ability to work and standard of living No new AEDs approved in over 5 years (U.S.) Few future treatments expected, particularly with a novel mode of action There is a strong need for a new treatment option AED = Anti-Epileptic Drug the next generation biopharma leader 35

36 Vimpat in epilepsy First choice add-on AED Novel, dual mode of action: Modulate sodium channel differently (selective enhancement of sodium channel slow inactivation) Only AED binding to collapsin response mediator protein 2 (CRMP-2) which could potentially have a disease modifying effect Additional seizure control regardless of current or prior therapy: 1 st or 2 nd generation AEDs Most patients were uncontrolled with nearly one-half having tried 7+ AEDs High long term retention rates: When patients start Vimpat, the majority stay on it.... and response is maintained over time AED = Anti-Epileptic Drug the next generation biopharma leader 36

37 Vimpat in epilepsy First choice add-on AED Well tolerated: Low level of sedation, cognitive and behavioral side effects Weight neutral Most common adverse events are all lower than key competitors Easy to use: Short titration No clinically significant drug-to-drug interactions Multiple formulations for expanded use (tablets, syrup and IV) the next generation biopharma leader 37

38 Vimpat Confidence Outstanding responder rates even though... 84% of patients were uncontrolled on 2-3 AEDs Patients had high baseline seizure frequency (10-15 seizures/28 days) normally a predictor for poor response Improved control when added to a wide range of AEDs including 1st and 2 nd generation AEDs Confidence of additional seizure control regardless of current or prior therapy *Indication for POS patients ( 16 years old). As demonstrated in three, placebo-controlled, double-blind clinical trials with 12 weeks maintenance phase evaluating the efficacy of VIMPAT as adjunctive therapy in 1,294 patients with POS aged 16 years and older who were not adequately controlled with one to three concomitant AEDs. Patients in clinical trials with VIMPAT may have been on more than one concomitant AED. Groupings done by patients who were receiving these AEDs as one of the concomitant AEDs in three placebo-controlled trials. the next generation biopharma leader 38

39 Vimpat Confidence The confidence of additional efficacy with manageable side effects Vimpat adverse events (AEs) were mild to moderate and decrease over time Most frequently reported AEs were dizziness, headache, nausea and diplopia Most common AEs were all similar or lower than key competitors As demonstrated in three placebo-controlled, double-blind clinical trials with a 12-week maintenance phase evaluating the efficacy and safety of VIMPAT mg/day as adjunctive therapy in 1,294 patients with POS aged 16 years and older who were not adequately controlled with one to three concomitant AEDs. 600 mg/day dose is not recommended. *n=337 **n=246 ***n=393. Adapted from reference 7 the next generation biopharma leader 39

40 Vimpat : Our next class-leading agent EU Vimpat epilepsy approval and launch expected in Sept'08 US Vimpat epilepsy file pending approval (filed Nov'07) From UCB, the makers of Keppra, the world s leading AED Leverage UCB's strong equity in epilepsy Outstanding launch readiness in place Leading share of voice to be delivered by the Keppra sales force + Assertive and rapid life cycle development and phase IV plan There is a strong need for a new treatment option the next generation biopharma leader 40

41 41 Roch Doliveux Chief Executive Officer Strategy update: Introduction of SHAPE Outlook 2008

42 UCB to become the next generation biopharma leader 42 With recent approvals, UCB has reached successfully the point in time to further focus. Execution Intense growth Realise the commercial potential of new products Breakthrough Launch a new generation of therapies that will make an even greater difference Increase investments in R&D Invest in pre-launch activities Improve costs Manage product life cycles and beyond

43 A challenging environment: the BioPharmaceutical industry 43 Declining R&D productivity Rising cost containment (including U.S.) Need to change the game Demonstrate value for patients and payers Focus on true innovation to meet patient medical needs Focus on unmet market / medical needs Decreasing success of traditional business model UCB has started transformation 4 years ago, on the right track to become the next generation biopharma leader

44 UCB with strong potential 44 Impressive late stage pipeline: CNS & Immunology Already several approvals: Cimzia /CD in the U.S. Neupro /RLS in EU (positive opinion) Vimpat /Epilepsy in EU (positive opinion) Five projects across both regions in filing process, Five projects in clinical phase III development Our two biggest products so far, Zyrtec and Keppra are at or nearing the end of their patent life As a proactive response to the challenges we face and the need to increase our competitive position, UCB has started an initiative called "SHAPE" to focus on an accelerated specialist transformation

45 SHAPE! 45 SHAPE is expected to Re-allocate resources Focus our investment into core areas: CNS and immunology Re-deploy UCB resources on its growth drivers Advance research and development efforts which should result in enhancing UCB's competitiveness and profitability in the fast-growing biopharma world. UCB has started an initiative called "SHAPE" to increase investments in core business areas to improve competitiveness and profitability while successfully delivering new medicines to patients.

46 UCB to SHAPE the organisation for the future UCB intends to shape the company for the future Focus on CNS and immunology in product and project portfolio Strategic geographic focus new ways of achieving its objectives, including best-in-class solutions of other industries Simplify the organisation UCB is reviewing its organisational effectiveness and efficiency, including a survey among 1,300 colleagues Re-allocate approx. 300 million to improve competitiveness and profitability within the next three years 46 to increase investments in new product launches, development and breakthrough research in its focused areas First details of SHAPE expected to be available by the end of the summer

47 SHAPE UCB: NewMedicines Delivering the breakthrough 47 In February 2008 UCB announced a two-fold focus for R and D Recognising the need for different environments and skill sets Strategic reorganisation to beat the odds in biopharma R&D, by dedicated resources and focus at each stage of R&D thereby optimizing UCB s investment in discovery research "UCB NewMedicines" is UCB s discovery research through to proof of concept organisation To deliver a strong and innovative pipeline to UCB To bring new medicines to patients with severe diseases in two therapeutic areas: CNS and immunology

48 What is different in UCB NewMedicines? 48 Networked R&D with a disseminated discovery organisation Two principal research hubs, one CNS, one immunology External incubators Open, collaborative research with strengthened external focus Discrete vibrant research units with devolved budgets Strong technology platforms underpinning new products targets, small and large molecules (separate and combined) Clinical knowledge and input at the heart of research

49 Mid-term Action Plan for UCB NewMedicines Advance the internal portfolio Deliver late pre-clinical projects rapidly to proof of concept Partnering and Licensing activity In-license pre-clinical/clinical phase I products to boost midterm pipeline Collaborate on rich seams of innovation and early programmes to complement our strengths and drive early projects Out-source transactional activities Out-sourcing to support both pharmaceutical sciences and chemistry 49

50 Outlook 2008 and beyond Revenue expected to exceed 3.3 billion Patent/exclusivity expirations of Zyrtec and Keppra in the U.S. Impact of currency deterioration Recurring EBITDA expected to reach approx. 650 million Impact of the Neupro issue is foreseen to be at approx. 30 million, compensated by synergies Net result as reported might be impacted significantly by potential one-time effects In 2009, recurring EBITDA is expected to be at least at the same level as increasing afterwards based on growth from newly launched products. Net result as reported in 2009 might also be impacted by one-time effects related to SHAPE initiative.

51 2008, another year of execution 51 Clinical milestones CDP791 in non-small-cell lung cancer Phase II study results Epratuzumab study for SLE 1 Global Phase IIb to start Brivaracetam in ULD 2 Phase III results Lacosamide in fibromyalgia Proof of concept trial results Rotigotine in fibromyalgia Phase II results (H2) Xyrem in fibromyalgia Phase III preliminary results (H2) Regulatory milestones Cimzia for RA Filed in the U.S.and Europe Cimzia in Crohn's CHMP appeal decision (Europe) Cimzia in Crohn's Approved by FDA Keppra in epilepsy - pediatric exclusivity Granted by FDA Neupro in RLS CHMP positive opinion (Europe) Vimpat in epilepsy CHMP positive opinion (Europe) Marketing milestones Cimzia in Crohn's Launched in Switzerland, launched the USA within 48 hours 1 SLE: systemic lupus erythematosus 2 ULD: Unverricht Lundborg disease

52 UCB The next generation biopharma leader 52 Your questions please Execution Intense growth Realise the commercial potential of new products Breakthrough Launch a new generation of therapies that will make an even greater difference Increase investments in R&D Invest in pre-launch activities Improve costs Manage product life cycles and beyond

53 53 Appendix

54 UCB's presence at forthcoming scientific conferences 54 August September October 12 th World Congress of Pain - Glasgow (UK) August th EFNS - Neurology - Madrid (Spain) August th European Association Study Diabetes - Rome, September 7-11 EU Sleep Research Society - Glasgow (UK), September 9-13 ANA - Salt Lake City, UT (USA), September EU Congress on Epileptology - Berlin (Germany), September The American - Orlando, FL (USA), October th European Conference Epilepsy & Society - Marseille (France), October th United European Gastroenterology Week - Vienna (Austria), October American College of Rheumatology - San Francisco, CA (USA), October November December SFN - Washington, DC (USA), November nd American Epilepsy Society - Seattle, WA (USA), December 5-6 7th Annual Advances in the Inflammatory Bowel Diseases - Hollywood, FL (USA), December 4-7, 2008

55 Your Investor Relations Team 55 Antje Witte, Vice President Corporate Communications & Investor Relations Phone antje.witte@ucb-group.com Mareike Mohr, Director Investor Relations (currently on maternity leave) Michael Tuck-Sherman, Business Analyst Phone: michael.tuck-sherman@ucb-group.com Isabelle Ghellynck, IR Coordinator Phone: isabelle.ghellynck@ucb-group.com